US 8859516
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
granted A61KA61K31/167A61K31/573
Quick answer
US patent 8859516 (Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes) held by Alnylam Pharmaceuticals, Inc. expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/167, A61K31/573, A61K31/713, A61K45/06